Efficacy of bevacizumab through an indwelling pleural catheter in non-small cell lung cancer patients with symptomatic malignant pleural effusion

被引:0
作者
Zeng, Hao [1 ]
Zhang, Yuanyuan [1 ]
Tan, Sihan [1 ]
Huang, Qin [1 ]
Pu, Xin [1 ]
Tian, Panwen [1 ,2 ]
Li, Yalun [1 ,2 ]
机构
[1] Sichuan Univ, West China Hosp, Lung Canc Ctr, Lung Canc Inst, 37 Guoxue Alley, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Pulm & Crit Care Med, State Key Lab Resp Hlth & Multimorbid,Precis Med K, Chengdu 610041, Sichuan, Peoples R China
基金
中国国家自然科学基金;
关键词
Bevacizumab; Indwelling pleural catheter; Non-small cell lung cancer; Malignant pleural effusion; Actionable mutations; THERAPY; EGFR; CLASSIFICATION; CISPLATIN; TUMORS;
D O I
10.1186/s12890-024-02886-1
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
BackgroundSeveral studies have indicated that intrapleural infusion of bevacizumab is an effective treatment for non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE). However, the impact of bevacizumab administered through an indwelling pleural catheter (IPC) on the prognosis of these patients is unknown.MethodsConsecutive advanced NSCLC patients with symptomatic MPE receiving an IPC alone or bevacizumab through an IPC were identified in a tertiary hospital. The patient characteristics and clinical outcomes were collected.ResultsA total of 149 patients were included, and the median age was 60.3 years. Males and nonsmokers accounted for 48.3% and 65.8%, respectively. A total of 69.8% (104/149) of patients harbored actionable mutations, including 92 EGFR-activating mutations, 11 ALK fusions, and 1 ROS1 fusion. A total of 81.9% (122/149) of patients received IPC alone, and 18.1% (27/149) received bevacizumab through an IPC. The incidence of spontaneous pleurodesis during the first 6 months was greater in the bevacizumab-treated group than in the IPC-treated group in the subgroup with actionable mutations (64.3% vs. 46.9%, P = 0.28). The median overall survival (OS) in patients with actionable mutations treated with bevacizumab through an IPC was 42.2 months, which was significantly longer than the 26.7 months in patients who received an IPC alone (P = 0.045). However, the median OS did not differ between the two arms in the subgroup without actionable mutations (10.8 vs. 41.0 months, P = 0.24). No significant difference between the bevacizumab through an IPC group and the IPC group was detected in the number of participants who had adverse events, either in patients with actionable mutations (14.3% vs. 8.4%; P = 0.42) or in patients without actionable mutations (16.7% vs. 12.8%; P = 1.00).ConclusionsBevacizumab through an IPC resulted in a significantly improved prognosis for NSCLC patients with MPE and actionable mutations. However, patients without actionable mutations do not benefit from bevacizumab through IPC.
引用
收藏
页数:11
相关论文
共 39 条
[1]   Update on the diagnosis and management of malignant pleural effusions [J].
Bashour, Sami, I ;
Mankidy, Babith J. ;
Lazarus, Donald R. .
RESPIRATORY MEDICINE, 2022, 196
[2]   ERS/EACTS statement on the management of malignant pleural effusions [J].
Bibby, Anna C. ;
Dorn, Patrick ;
Psallidas, Ioannis ;
Porcel, Jose M. ;
Janssen, Julius ;
Froudarakis, Marios ;
Subotic, Dragan ;
Astoul, Phillippe ;
Licht, Peter ;
Schmid, Ralph ;
Scherpereel, Arnaud ;
Rahman, Najib M. ;
Cardillo, Giuseppe ;
Maskell, Nick A. .
EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (01)
[3]   Thoracic ultrasound as a predictor of pleurodesis success at the time of indwelling pleural catheter removal [J].
Chaddha, Udit ;
Agrawal, Abhinav ;
Bhavani, Sivasubramanium V. ;
Sivertsen, Kimberly ;
Donington, D. Jessica ;
Ferguson, Mark K. ;
Murgu, Septimiu .
RESPIROLOGY, 2021, 26 (03) :249-254
[4]   The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer [J].
Chansky, Kari ;
Detterbeck, Frank C. ;
Nicholson, Andrew G. ;
Rusch, Valerie W. ;
Vallieres, Eric ;
Groome, Patti ;
Kennedy, Catherine ;
Krasnik, Mark ;
Peake, Michael ;
Shemanski, Lynn ;
Bolejack, Vanessa ;
Crowley, John J. ;
Asamura, Hisao ;
Rami-Porta, Ramon .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (07) :1109-1121
[5]   Concurrent Blockade of Endothelial EGFR and VEGF Signaling on Malignant Associated Pleural Fluid Induced Angiogenesis: From Clinic to Bench [J].
Chen, Wei-Teing ;
Lin, Yu-Huei ;
Changchien, Chih-Ying ;
Chen, Ying ;
Chang, Hsin-Han ;
Tsai, Wen-Chiuan ;
Tsai, Hao-Chung ;
Wang, Chieh-Yung ;
Shen, Ming-Sheng ;
Cheng, Li-Ting ;
Tsai, Chen-Liang .
BIOMEDICINES, 2021, 9 (10)
[6]   Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion [J].
Du, Nan ;
Li, Xiaosong ;
Li, Fang ;
Zhao, Hui ;
Fan, Zhongyi ;
Ma, Junxun ;
Fu, Yan ;
Kang, Huanrong .
ONCOLOGY REPORTS, 2013, 29 (06) :2332-2340
[7]   Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines [J].
Ettinger, David S. ;
Wood, Douglas E. ;
Aisner, Dara L. ;
Akerley, Wallace ;
Bauman, Jessica R. ;
Bharat, Ankit ;
Bruno, Debora S. ;
Chang, Joe Y. ;
Chirieac, Lucian R. ;
D'Amico, Thomas A. ;
Dilling, Thomas J. ;
Dowell, Jonathan ;
Gettinger, Scott ;
Gubens, Matthew A. ;
Hegde, Aparna ;
Hennon, Mark ;
Lackner, Rudy P. ;
Lanuti, Michael ;
Leal, Ticiana A. ;
Lin, Jules ;
Loo, Billy W., Jr. ;
Lovly, Christine M. ;
Martins, Renato G. ;
Massarelli, Erminia ;
Morgensztern, Daniel ;
Ng, Thomas ;
Otterson, Gregory A. ;
Patel, Sandip P. ;
Riely, Gregory J. ;
Schild, Steven E. ;
Shapiro, Theresa A. ;
Singh, Aditi P. ;
Stevenson, James ;
Tam, Alda ;
Yanagawa, Jane ;
Yang, Stephen C. ;
Gregory, Kristina M. ;
Hughes, Miranda .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (03) :254-266
[8]   Management of Malignant Pleural Effusions An Official ATS/STS/STR Clinical Practice Guideline [J].
Feller-Kopman, David J. ;
Reddy, Chakravarthy B. ;
DeCamp, Malcolm M. ;
Diekemper, Rebecca L. ;
Gould, Michael K. ;
Henry, Travis ;
Iyer, Narayan P. ;
Lee, Y. C. Gary ;
Lewis, Sandra Z. ;
Maskell, Nick A. ;
Rahman, Najib M. ;
Sterman, Daniel H. ;
Wahidi, Momen M. ;
Balekian, Alex A. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 198 (07) :839-849
[9]   Is Systemic Anticancer Therapy Associatec With Higher Rates of Malignant Pleural Effusion Control in People With Pharmacologically Sensitive Tumors? A Retrospective Analysis of Prospectively Collected Data [J].
Holling, Nina ;
Patole, Sonia ;
Medford, Andrew R. L. ;
Maskell, Nick A. ;
Bibby, Anna C. .
CHEST, 2021, 160 (05) :1915-1924
[10]   Diagnosis and Management of Malignant Pleural Effusion: A Decade in Review [J].
Jacobs, Blake ;
Sheikh, Ghias ;
Youness, Houssein A. ;
Keddissi, Jean, I ;
Abdo, Tony .
DIAGNOSTICS, 2022, 12 (04)